AMBIGUOUS RESULTS

ENDURANCE trial: two years of lenalidomide matches lifelong maintenance in myeloma

The ECOG-ACRIN Phase 3 trial found near-identical seven-year survival with fixed two-year lenalidomide versus indefinite therapy, while indefinite dosing carried more toxicity and second cancers.

By AppliedXLJuly 15, 2026Trial NCT01863550

Executive Summary

A randomized Phase 3 trial in newly diagnosed multiple myeloma found that stopping lenalidomide maintenance after two years produced the same long-term overall survival as continuing it indefinitely.
Patients who stayed on lenalidomide indefinitely had more fatigue, anemia, and diarrhea, plus a higher rate of second primary cancers over five years, without gaining any survival benefit for that added exposure.
Indefinite lenalidomide until progression is the current standard maintenance approach after induction in standard-risk myeloma patients who did not receive a stem cell transplant, making a validated stopping point a change to how that regimen is managed rather than a new drug or mechanism.
The trial speaks to standard-risk, transplant-ineligible patients specifically, and the published summary available does not carry the effect size or statistical detail that would let a reader judge the precision of the survival equivalence beyond the two reported rates.

The finding

ENDURANCE (E1A11), registered as NCT01863550, randomized 516 patients with standard-risk multiple myeloma who had completed initial treatment but were not candidates for upfront stem cell transplantation. One arm received lenalidomide until disease progression, the prevailing standard of care; the other received lenalidomide for a fixed two years. After nearly seven years of follow-up, overall survival was 68.6% in the indefinite-duration arm versus 69.0% in the two-year arm, a gap the trial's own authors characterized as equivalent rather than as a win for either arm. NCT01863550+1

The trade-off

Indefinite dosing did not buy a survival edge, but it did carry a cost. Patients on lenalidomide until progression had higher rates of fatigue, anemia, and diarrhea than those on the two-year fixed schedule, and a higher incidence of second primary cancers over five years. Lead author Shaji Kumar, co-chair of the ECOG-ACRIN Myeloma Committee, said the trial resolves a question clinicians had lacked data to answer: "Our trial results show that two years is sufficient and that continuing the drug longer adds toxicity without extending life". Senior author S. Vincent Rajkumar said the findings support a fixed-duration approach becoming "the new standard of care, at least for standard-risk patients". Landmark

How it was run

ENDURANCE is an open-label, randomized, four-arm Phase 3 trial run by the ECOG-ACRIN Cancer Research Group with National Cancer Institute collaboration, enrolling 1,087 patients overall against the study's registered target, with the maintenance-duration comparison analyzed in 516 of them. The trial's registered primary outcome measure is overall survival for the maintenance analysis. Enrollment began in December 2013, and the primary completion date moved once, from November 2023 to November 2025, before the trial's current active-not-recruiting status. Sagar Lonial, a co-author, said this is the first randomized trial to show that limited-duration lenalidomide maintenance does not sacrifice survival in patients who did not receive a transplant and were treated with triplet induction. NCT01863550+1

Where the drug stands

Lenalidomide already carries multiple approved generic formulations in the United States, with 18 approvals on record spanning sponsors including Apotex, Mylan, and Hetero Labs, reflecting its established, off-patent status in myeloma rather than a molecule awaiting a first approval decision. The ENDURANCE result does not change what the drug is approved to do; it changes how long clinicians might reasonably keep a standard-risk patient on it. Fifty trials in the competitive set use lenalidomide as a comparator or backbone arm, mostly newer combinations pairing it with agents like daratumumab, elranatamab, or linvoseltamab against BCMA or CD3 targets in transplant-eligible or newly diagnosed populations, underscoring that lenalidomide's role now sits mainly as the maintenance backbone against which next-generation combinations are measured.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.